ReviewEuropean journal of medical research2011
Epidemiology and antifungal resistance in invasive Aspergillosis according to primary disease: review of the literature.
Review in European journal of medical research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers.Antimicrobial agents and chemotherapy · 2023Trial
- Current Evidence on Voriconazole Exposure and Individualized Therapy for Aspergillosis.Infection and drug resistance · 2026Review
- Loss of theMicrobiology spectrum · 2025Article
- SAR study of N'-(Salicylidene)heteroarenecarbohydrazides as promising antifungal agents.Bioorganic & medicinal chemistry · 2024Article
- Virulence capacity of differentFrontiers in immunology · 2023Article
- Therapeutic Approaches for CombatingCurrent drug targets · 2022Review
- Novel Antifungal Agents and Their Activity againstJournal of fungi (Basel, Switzerland) · 2020Review
- Detecting Azole-Antifungal Resistance inJournal of fungi (Basel, Switzerland) · 2020Review
- Novel Hit Compounds as Putative Antifungals: The Case ofMolecules (Basel, Switzerland) · 2019Article
- Antifungal Resistance in Clinical Isolates ofJournal of fungi (Basel, Switzerland) · 2019Article
- Unravelling species boundaries in thePersoonia · 2018Article
- Acylhydrazones as Antifungal Agents Targeting the Synthesis of Fungal Sphingolipids.Antimicrobial agents and chemotherapy · 2018Article
- Regulation of Sterol Biosynthesis in the Human Fungal PathogenFrontiers in microbiology · 2017Review
- Special Issue: Novel Antifungal Drug Discovery.Journal of fungi (Basel, Switzerland) · 2016Article
- Article
- In Vivo Synergy of Amphotericin B plus Posaconazole in Murine Aspergillosis.Antimicrobial agents and chemotherapy · 2016Article
- The molecular mechanism of azole resistance in Aspergillus fumigatus: from bedside to bench and back.Journal of microbiology (Seoul, Korea) · 2015Review
- Cryptic and rare Aspergillus species in Brazil: prevalence in clinical samples and in vitro susceptibility to triazoles.Journal of clinical microbiology · 2014Article
- Does fungicide application in vineyards induce resistance to medical azoles in Aspergillus species?Environmental monitoring and assessment · 2014Article
- The application of laser microdissection in molecular detection and identification of aspergillus fumigatus from murine model of acute invasive pulmonary aspergillosis.Mycopathologia · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aspergilli, less susceptible to antifungals emerge and resistance to azoles have been found mainly in Aspergillus fumigatus; this has launched a new phase in handling aspergillosis. Resistant strains have currently been reported from Belgium, Canada, China, Denmark, France, Norway, Spain, Sweden, The Netherlands, UK and the USA. Centres in the UK (Manchester) and The Netherlands (Nijmegen) have described particularly high frequencies (15 and 10% respectively), and a significant increase in azole resistance in recent years. The reason of this high incidence may be due to long term azole therapy in patients with chronic aspergillosis in Manchester, and due to high use of agricultural azoles in Nijmegen. The primary underlying mechanism of resistance is as a result of alterations in the cyp51A target gene, with a variety of mutations found in clinical isolates and one genotype identified in the environmental (LH98). Reports on well documented in vitro and in vivo resistance to echinocandins are rare for Aspergillus species and resistance may be under-diagnosed as susceptibility testing is less frequently performed due to technical reasons.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.